Xeris Biopharma (NASDAQ:XERS) Releases Quarterly Earnings Results

Xeris Biopharma (NASDAQ:XERS) released its quarterly earnings results on Thursday. The company reported $0.01 earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $79.83 million. Xeris Biopharma had a negative return on equity of 556.27% and a net margin of 3.81%.

Here are the key takeaways from Xeris Biopharma’s conference call:

• Q1 net product revenue rose 43% to $82.5M (total revenue $83.1M) and management raised FY revenue guidance to $380M–$390M, lifting the low end of prior guidance.
• RECORLEV nearly doubled to $49.8M on record referrals and new patient starts, and the company completed its commercial expansion (≈80 reps, targets increased to ~12,000), with incremental impact expected in H2.
• Gvoke was flat at $20.8M and underperformed internal expectations due to Medicare policy/plan resets that raised out‑of‑pocket costs and reduced prescription fills; management expects a recovery later in the year.
• The pipeline candidate XP‑8121 is on track to start Phase III later this year, leveraging the company’s XeriSol and device capabilities, with R&D spend planned to increase to support the program.
• Profitability metrics improved—gross margin 87% (+2%), adjusted EBITDA $15.1M, and net income $2.2M—with management reiterating a commitment to positive adjusted EBITDA for 2026 despite higher SG&A and R&D investments.

Xeris Biopharma Stock Performance

Xeris Biopharma stock opened at $6.53 on Friday. The firm has a market capitalization of $1.13 billion, a P/E ratio of 108.83 and a beta of 0.85. The stock has a fifty day moving average price of $5.92 and a two-hundred day moving average price of $6.96. The company has a debt-to-equity ratio of 16.10, a current ratio of 2.19 and a quick ratio of 1.57. Xeris Biopharma has a 52-week low of $4.30 and a 52-week high of $10.08.

Wall Street Analysts Forecast Growth

XERS has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Xeris Biopharma in a report on Monday, March 2nd. Weiss Ratings upgraded shares of Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Finally, Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.80.

Insider Activity at Xeris Biopharma

In other news, Director James Aloysius Brady sold 10,834 shares of the firm’s stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $5.54, for a total transaction of $60,020.36. Following the completion of the sale, the director owned 89,166 shares of the company’s stock, valued at approximately $493,979.64. This trade represents a 10.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Beth Hecht sold 16,667 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $6.23, for a total transaction of $103,835.41. Following the sale, the insider directly owned 1,193,173 shares of the company’s stock, valued at approximately $7,433,467.79. The trade was a 1.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 60,835 shares of company stock valued at $367,860. Company insiders own 6.47% of the company’s stock.

Institutional Trading of Xeris Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of XERS. Cetera Investment Advisers increased its position in Xeris Biopharma by 3.9% in the second quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock worth $216,000 after purchasing an additional 1,735 shares during the period. Royal Bank of Canada grew its stake in shares of Xeris Biopharma by 6.5% during the 4th quarter. Royal Bank of Canada now owns 38,636 shares of the company’s stock worth $304,000 after acquiring an additional 2,351 shares in the last quarter. Kestra Advisory Services LLC acquired a new position in shares of Xeris Biopharma during the 4th quarter worth about $25,000. The Manufacturers Life Insurance Company grew its stake in shares of Xeris Biopharma by 7.0% in the second quarter. The Manufacturers Life Insurance Company now owns 54,472 shares of the company’s stock valued at $254,000 after buying an additional 3,562 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Xeris Biopharma by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after buying an additional 3,594 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.